Despite numerous efforts to target EGFR, commonly dysregulated in GBM, targeted therapeutic approaches against EGFR have not achieved the same degree of success as seen in other tumour types, particularly when compared to non-small cell lung cancer (NSCLC) [4,5]. This evidence concerns the gene EGFR and neoplasm.